Objective: To determine whether the alternate glycemic markers, fructosamine (FA), glycated albumin (GA), and 1,5-anhydroglucitol (1,5AG), predict glycemic variability captured by continuous glucose monitoring (CGM) in obese youth with prediabetes and type 2 diabetes (T2D).
| INTRODUCTION
Hemoglobin A1c (HbA1c) is the traditional test for monitoring glycemic control in patients with diabetes and, since 2010, has become a standard test for diagnosing and monitoring prediabetes and type 2 diabetes in youth. 1, 2 Debate remains, however, over the optimal tools for prediabetes and diabetes screening and monitoring in obese youth. [3] [4] [5] Alternate markers of glycemia, specifically fructosamine (FA), glycated albumin (GA), and 1,5-anhydroglucitol (1,5AG), have been proposed as better measures of glycemic control and glucose variability than HbA1c in certain scenarios. [6] [7] [8] [9] [10] [11] There is also increasing evidence to suggest that glucose fluctuations, above and beyond average glycemia, play an important role in the increased risk for microvascular and macrovascular complications in diabetes.
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Although the availability of data on the relevance of these alternate markers in adults is growing, there are limited data on their utility in obese, dysglycemic youth, a high-risk group who may have a more aggressive disease than adults.
14, 15 1,5 anhydroglucitol is a naturally occurring monosaccharide obtained primarily from the diet and a steady body pool is maintained via renal excretion and reabsorption. Renal reabsorption of 1,5AG is competitively inhibited by glycosuria and serum 1,5AG decreases as serum glucose rises above 180 mg/dL; serum levels reflect glycemia over the preceding 2-14 days. 16, 17 Several studies support the utility of 1,5AG as a more sensitive measure of short-term glucose changes and post-prandial glucose excursions than HbA1c in adults with type 1 and type 2 diabetes. 10, 18, 19 However, other studies have not confirmed these findings 20, 21 and some have found that 1,5AG may only be useful in persons with moderate to well-controlled diabetes with HbA1c <8%. 16, 20, 22 Fructosamine and glycated albumin are glycated ketoamines that reflect short-term blood glucose changes over the preceding 2 to 3 weeks. GA in particular has been proposed to be a better predictor of glucose variability and excursions than HbA1c. 7, 23, 24 In large adult studies, both of the alternate markers have also been found to correlate with microvascular 25, 26 and macrovascular complications. 27 Data on the significance of these alternate glycemic markers in youth are lacking. A few studies have evaluated alternate markers as screening tools for prediabetes and type 2 diabetes in obese youth. 28, 29 However, the relationships between these alternate markers and measures of free-living glycemia in this population have not previously been explored. This study aimed to determine the relationships among FA, GA, and 1,5AG and glycemia, with a focus on glycemic variability, as measured by continuous glucose monitoring (CGM).
| RESEARCH DESIGN AND METHODS

| Study population and design
The study population was recruited from weight management and endocrine clinics at Children's Hospital Colorado, as well as primary care, school-based, and community health clinics in Denver, Colorado.
Eligible participants included youth 10 to 18 years of age with a BMI ≥85th%ile. Participants with HbA1c ≥ 5.7%, from a larger study (n = 48) of CGM in obese adolescents were included in this secondary analysis, as were participants with type 2 diabetes who had CGM data available (n = 8).
Exclusion criteria included anemia, hemoglobinopathy, chronic illness likely to affect red cell life span, pregnancy or breast feeding, positive islet-cell antibodies, medications affecting glycemia such as systemic steroids and atypical antipsychotics, and use of diabetes medications other than metformin and insulin. The study was approved by the Colorado Multiple Institutional Review Board (Aurora, Colorado). 
| Study visit
| CGM data
Only participants with a minimum of 48 hours of continuous CGM data (ie 576 continuous glucose data points) were analyzed. The following CGM variables were calculated: average sensor glucose, peak sensor glucose, area under the curve (AUC), area under the curve above 180 mg/dL (AUC180), standard deviation (SD), % time spent ≥140 mg/dL, % time spent ≥200 mg/dL, and mean amplitude of glycemic excursion (MAGE). 30 
| STATISTICAL ANALYSIS
The distribution of all variables was examined prior to analysis.
Descriptive statistics reported include median, minimum, and maximum for continuous variables, and frequency and percent for categorical variables. To examine the association of the various markers of glycemia with CGM variables, Spearman correlation coefficients were calculated. Linear models were then used to examine the association of the alternative markers with measures of glycemic variability (MAGE, SD, AUC 180) after controlling for HbA1c. In these models, the semi-partial ω 2 , which represents the proportion of variability in the outcome accounted for by the predictor after the other variables have been taken into account, was used as a measure of effect size.
Analyses are considered hypothesis-generating, so no adjustment was made for multiple testing. All analyses were conducted using SAS software version 9.4 (Cary, North Carolina).
| RESULTS
A total of 56 participants with CGM data and HbA1c ≥ 5.7 were included in this analysis. Descriptive statistics are presented in Table 1 . Participants had a median age of 14.3 years (range 10-18 years), were predominantly Hispanic and female with a median BMI at the 99%ile. Forty-eight individuals had an HbA1c of 5.7%-6.4%
and 8 had an HbA1c ≥ 6.5%. Eight individuals with known T2D were included in the study and of these, three had HbA1c < 6.5%. Of the 8 with known T2D, 5 were on metformin, 1 on insulin alone, 1 on metformin and insulin, and 1 was not on medication treatment for diabetes. Those without a known history of diabetes also underwent OGTT and 20 had normal glucose tolerance, 23 had impaired glucose tolerance, and 2 had diabetes by OGTT. Overall median (25th%ile, 75th%ile) values for measures of glycemia are presented in Table 1 .
The correlations between glycemic markers (FA, GA, 1,5AG, and HbA1c) and CGM variables are presented in Table 2 . FA correlated significantly with mean sensor glucose, peak sensor glucose, AUC, MAGE, and % time spent >120, >140, and >200 mg/dL. GA correlated significantly with the same CGM variables as FA and, additionally, with CGM SD, and AUC180. 1,5AG correlated significantly with peak sensor glucose, SD, MAGE, and AUC-180. HbA1c correlated with average sensor glucose, AUC, SD, MAGE, and % time spent >120 and >140 mg/dL, but not with peak sensor glucose, AUC180, nor % time spent >200 mg/dL. Figure 1 shows scatterplots of the relationships between glycemic markers HbA1c, FA, GA, 1,5AG, and glucose variability (SD and MAGE). In this figure, we identified participants with T2D separately from those with prediabetes. The correlations were significant in the T2D cohort for all glycemic markers and glucose variability, and in participants with prediabetes, significant only between GA and MAGE (P < 0.05).
We then used linear models to examine the association of FA, GA, and 1,5 AG with glycemic variability while controlling for HbA1c, to determine if alternate markers predicted variability beyond that explained by HbA1c alone (Table 3) . After controlling for HbA1c, FA independently predicted MAGE and SD; GA independently predicted MAGE and SD; 1,5AG independently predicted MAGE. In these models, the measure of effect size (ω 2 ) was largest for GA when predicting MAGE and SD. . 31 Yet interest is growing in the utility of alternate glycemic markers for monitoring diabetes control [32] [33] [34] and a number of large cross-sectional and prospective studies, many conducted in Asia where GA has been used more widely than in the US, have found FA and GA to be potentially useful tools with good sensitivity and specificity for diagnosing and monitoring diabetes when compared to HbA1c, FPG, and/or 2-hour with T2D by OGTT definitions), FA and HbA1c both did a poor job at detecting dysglycemia (prediabetes and T2D combined). 57 In contrast, 1 study of obese, insulin-resistant youth found that 1,5AG at a cutpoint of <17 mcg/mL and HbA1c at a cutpoint of ≥6% both had excellent sensitivity and specificity when screening for T2D diabetes. 29 We previously reported that although FA, GA, and 1,5AG did not do a good job discriminating those with prediabetes, they were good predictors of T2D in obese youth (ROC AUCs of 0.92-0.98) when compared to HbA1c and OGTT. 28 Given that treatment beyond lifestyle intervention is only recommended in those with T2D, not prediabetes, these markers may be beneficial in diagnosing T2D and identifying those who would benefit from medication intervention, particularly in circumstances where OGTTs may be difficult to obtain, or HbA1c unreliable (anemia, hemoglobinopathies, chronic illness, etc).
| DISCUSSION
In the current study, we compared the relationships among alternate glycemic indices with glycemic variability captured on CGM.
Only 1 small study has previously examined the relationship between alternate glycemic markers and CGM in youth. 21 In that study of In Figure 1 , participants with T2D had greater glycemic variability that correlated with the distribution of glycemic markers, while participants with prediabetes had less glycemic variability on CGM. As a result, the significant relationships between measures of glycemic variability and the alternate markers are driven primarily by the T2D cohort. Also of note, the correlations between the alternate markers and both SD and MAGE in the 2 cohorts were very similar. This finding of a high correlation between SD and MAGE, in 1 study up to 0.9, has been previously reported. 58 Ultimately, whether or not these early glycemic In summary, this is the first study examining the relationship between alternate glycemic markers and CGM in obese youth with prediabetes and T2 diabetes. In this population, all 3 alternate markers correlated with multiple CGM variables and give information about glycemic variability above and beyond that provided by HbA1c.
Longitudinal studies are required to better understand the association between youth-onset abnormalities in these alternate markers as well as the impact of early glycemic variability on future development of microvascular and macrovascular complications. 
